Old Web
English
Sign In
Acemap
>
authorDetail
>
Julia Asche
Julia Asche
Oncology
Resminostat
Pathology
Internal medicine
Medicine
3
Papers
16
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.
2017
Journal of Clinical Oncology
Michael Bitzer
Marius Horger
Tom M. Ganten
Ulrich M. Lauer
M. Woerns
Jens T. Siveke
Matthias Dollinger
Guido Gerken
Henning Wege
Edoardo G. Giannini
Vittorina Zagonel
Umberto Cillo
Franco Trevisani
Armando Santoro
Vincenzo Montesarchio
Bernhard Hauns
Julia Asche
R. Jankowsky
Anna Mais
Bernd Hentsch
Show All
Source
Cite
Save
Citations (8)
Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.
2017
Journal of Clinical Oncology
Henning Schulze-Bergkamen
Dirk Jaeger
Hans-Georg Kopp
Frank Mayer
Michael Bitzer
Anna Mais
Karin Resemann
Bernhard Hauns
Julia Asche
Stefan W. Henning
Bernd Hentsch
Show All
Source
Cite
Save
Citations (1)
Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.
2017
Journal of Clinical Oncology
Michael Bitzer
Tom M. Ganten
M.A. Woerns
Jens T. Siveke
Matthias Dollinger
M. E. Scheulen
Henning Wege
Edoardo G. Giannini
Umberto Cillo
Franco Trevisani
Armando Santoro
Vincenzo Montesarchio
Anna Mais
Bernhard Hauns
Julia Asche
Thomas Herz
Stefano Pegoraro
Aldo Ammendola
Stefan W. Henning
Bernd Hentsch
Show All
Source
Cite
Save
Citations (7)
1